Matsumoto Satoru, Takahashi Masahiro, Ishizu Hiroyuki, Takahashi Hiromasa, Masuko Hiroyuki, Tanaka Kouichi, Hata Tsunetake, Yamagami Hideki, Takahashi Shusaku, Tahara Munenori, Ueki Shinya, Kuji Mariko, Tanioka Toshiro
Dept. of Surgery, Hokkaido P. W. F. A. C Sapporo-Kosei General Hospital.
Gan To Kagaku Ryoho. 2014 Nov;41(12):2405-7.
The recommended dose of imatinib for recurrent gastrointestinal stromal tumors (GIST) is 400mg/day. However, adverse effects limit the use of the standard dose in elderly patients. We report a case of an elderly patient with recurrent GIST, where long-term control of the disease was achieved with low-dose imatinib therapy. An 86-year-old man presenting with tarry stool was admitted to the hospital; upper GI endoscopy revealed a gastric submucosal tumor of the stomach at the posterior wall of the cardia. Partial gastrectomy was performed laparoscopically. The submucosal lesion was histopathologically diagnosed as malignant GIST. Administration of imatinib was initiated 17 months after surgery because of recurrence of GIST. The initial dose of imatinib was 400mg/day, which was later adjusted to 200mg or 300 mg/day because of adverse effects. Though imatinib was withdrawn several times due to strong side effects, the disease was well controlled for 6 years after surgery.
伊马替尼用于复发性胃肠道间质瘤（GIST）的推荐剂量为每日400毫克。然而，不良反应限制了标准剂量在老年患者中的使用。我们报告一例老年复发性GIST患者，通过低剂量伊马替尼治疗实现了疾病的长期控制。一名86岁男性因黑便入院；上消化道内镜检查发现贲门后壁胃有一个胃黏膜下肿瘤。通过腹腔镜进行了部分胃切除术。黏膜下病变经组织病理学诊断为恶性GIST。由于GIST复发，术后17个月开始给予伊马替尼治疗。伊马替尼初始剂量为每日400毫克，后因不良反应调整为每日200毫克或300毫克。尽管因强烈副作用多次停用伊马替尼，但术后6年疾病得到了良好控制。
